{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:43:22Z","timestamp":1771569802363,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding SupporXingsheng Liu","award":["XMLX201702"],"award-info":[{"award-number":["XMLX201702"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant pleural mesothelioma (MPM) is a rare tumor in the\u00a0pleura. This study was carried out to identify key genes and pathways that may be involved in MPM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Microarray datasets GSE51024 and GSE2549 were analyzed for differentially expressed genes (DEGs) between normal and MPM tissues. The identified DEGs were subjected to functional analyses using bioinformatics tools.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 276 DEGs were identified, consisting of 187 downregulated and 79 upregulated genes. Gene ontology and Kyoto encyclopedia of genes and genomes pathway enrichment analysis indicated that the DEGs were enriched in extracellular structure organization, extracellular matrix, and ECM\u2212receptor interaction. Due to high degree of connectivity among 24 hub genes, EZH2 and HMMR are likely to play roles in the carcinogenesis and progression of MPM. The two genes were found over-expressed in MPM tissues. Patients with elevated EZH2 and HMMR expressions had poor overall survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>EZH2 and HMMR are identified to be the hub genes for MPM and they may be further characterized to better understand the molecular mechanisms underlying the carcinogenesis of MPM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-021-00954-7","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T19:04:18Z","timestamp":1618340658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identification of genes and pathways involved in malignant pleural mesothelioma using bioinformatics methods"],"prefix":"10.1186","volume":"14","author":[{"given":"Xingsheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaojun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7641-6350","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"6","key":"954_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","volume":"39","author":"J Remon","year":"2013","unstructured":"Remon J, Lianes P, Martinez S, Velasco M, Querol R, Zanui M. Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev. 2013;39(6):584\u201391.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"954_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/resp.12517","volume":"20","author":"SL Leong","year":"2015","unstructured":"Leong SL, Zainudin R, Kazan-Allen L, Robinson BW. Asbestos in Asia. Respirology. 2015;20(4):548\u201355.","journal-title":"Respirology"},{"issue":"18","key":"954_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1172\/jci.insight.128474","volume":"4","author":"M Hamaidia","year":"2019","unstructured":"Hamaidia M, Gazon H, Hoyos C, Hoffmann GB, Louis R, Duysinx B, et al. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. JCI Insight. 2019;4(18):66.","journal-title":"JCI Insight"},{"key":"954_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2018.07.007","volume":"124","author":"K Suveg","year":"2018","unstructured":"Suveg K, Putora PM, Berghmans T, Glatzer M, Kovac V, Cihoric N. Current efforts in research of pleural mesothelioma\u2014an analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12\u20138.","journal-title":"Lung Cancer"},{"issue":"4","key":"954_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316.","journal-title":"Nat Genet"},{"issue":"8","key":"954_CR6","first-page":"519","volume":"96","author":"A Ernst","year":"2017","unstructured":"Ernst A, Schlattmann P, Waldfahrer F, Westhofen M. Laryngorhinootologie. 2017;96(8):519\u201321.","journal-title":"Laryngorhinootologie"},{"issue":"1\u20132","key":"954_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mrfmmm.2009.09.003","volume":"671","author":"F Gemignani","year":"2009","unstructured":"Gemignani F, Neri M, Bottari F, Barale R, Canessa PA, Canzian F, et al. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. Mutat Res. 2009;671(1\u20132):76\u201383.","journal-title":"Mutat Res"},{"key":"954_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","volume":"12","author":"S Comertpay","year":"2014","unstructured":"Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, et al. Evaluation of clonal origin of malignant mesothelioma. J Transl Med. 2014;12:301.","journal-title":"J Transl Med"},{"issue":"1","key":"954_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","volume":"77","author":"S Cedres","year":"2012","unstructured":"Cedres S, Montero MA, Martinez P, Martinez A, Rodriguez-Freixinos V, Torrejon D, et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer. 2012;77(1):192\u20138.","journal-title":"Lung Cancer"},{"issue":"1","key":"954_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","volume":"90","author":"T Yamagishi","year":"2015","unstructured":"Yamagishi T, Fujimoto N, Nishi H, Miyamoto Y, Hara N, Asano M, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90(1):111\u20137.","journal-title":"Lung Cancer"},{"issue":"6","key":"954_CR11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","volume":"25","author":"MB Suraokar","year":"2014","unstructured":"Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, et al. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014;25(6):1184\u201392.","journal-title":"Ann Oncol"},{"issue":"4","key":"954_CR12","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gng015","volume":"31","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"954_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"954_CR14","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"954_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1593\/neo.07112","volume":"9","author":"DR Rhodes","year":"2007","unstructured":"Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166\u201380.","journal-title":"Neoplasia"},{"issue":"8","key":"954_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649\u201358.","journal-title":"Neoplasia"},{"issue":"8","key":"954_CR17","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-08-2755","volume":"15","author":"AV Ivanova","year":"2009","unstructured":"Ivanova AV, Goparaju CM, Ivanov SV, Nonaka D, Cruz C, Beck A, et al. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clin Cancer Res. 2009;15(8):2602\u201311.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"954_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1365-2559.2003.01568.x","volume":"42","author":"R Kaarteenaho-Wiik","year":"2003","unstructured":"Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL. Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology. 2003;42(3):280\u201391.","journal-title":"Histopathology"},{"key":"954_CR19","doi-asserted-by":"crossref","unstructured":"Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol. 2016;11(10):1615\u201326.","DOI":"10.1016\/j.jtho.2016.05.020"},{"issue":"2","key":"954_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","volume":"10","author":"SH Ou","year":"2015","unstructured":"Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015;10(2):387\u201391.","journal-title":"J Thorac Oncol"},{"key":"954_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2019.02.004","volume":"130","author":"M Yoshimura","year":"2019","unstructured":"Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, et al. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Lung Cancer. 2019;130:187\u201393.","journal-title":"Lung Cancer"},{"issue":"4","key":"954_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajmg.a.61066","volume":"179","author":"S Griffiths","year":"2019","unstructured":"Griffiths S, Loveday C, Zachariou A, Behan LA, Chandler K, Cole T, et al. EED and EZH2 constitutive variants: a study to expand the Cohen\u2013Gibson syndrome phenotype and contrast it with Weaver syndrome. Am J Med Genet A. 2019;179(4):588\u201394.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"954_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00428-018-2384-3","volume":"473","author":"A Gango","year":"2018","unstructured":"Gango A, Batai B, Varga M, Kapczar D, Papp G, Marschalko M, et al. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Virchows Arch. 2018;473(4):453\u201362.","journal-title":"Virchows Arch"},{"issue":"11","key":"954_CR24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"954_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","volume":"18","author":"CD Kemp","year":"2012","unstructured":"Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2012;18(1):77\u201390.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"954_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1039\/C7IB00002B","volume":"9","author":"SB Bahrami","year":"2017","unstructured":"Bahrami SB, Tolg C, Peart T, Symonette C, Veiseh M, Umoh JU, et al. Receptor for hyaluronan mediated motility (RHAMM\/HMMR) is a novel target for promoting subcutaneous adipogenesis. Integr Biol (Camb). 2017;9(3):223\u201337.","journal-title":"Integr Biol (Camb)"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-00954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-021-00954-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-00954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T19:15:00Z","timestamp":1618341300000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-021-00954-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["954"],"URL":"https:\/\/doi.org\/10.1186\/s12920-021-00954-7","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work does not involve human or animal study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}